A randomised phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole from 5 to 10 years.
Following five years of an AI and any duration of prior tamoxifen, women who received letrozole for five additional years had a
34% lower risk of recurrence than those who received placebo.
The trial was led by the Canadian Cancer Trials Group with participation from the National Clinical Trials Network.
These results were discussed in ASCO’s Plenary Session, which features four abstracts deemed to have the greatest potential to impact patient care, out of the more than 5,000 abstracts featured at the ASCO Annual Meeting.
“Women with early-stage hormone-receptor positive breast cancer face an indefinite risk of relapse,” said lead study author Paul Goss, MD, FRCP, PhD, director of Breast Cancer Research at Massachusetts General Hospital in Boston, Massachusetts and Professor of Medicine at Harvard Medical School. “The study provides direction for many patients and their doctors, confirming that prolonging aromatase inhibitor therapy can further reduce the risk of breast cancer recurrences. Longer AI therapy also showed a substantial breast cancer preventative effect in the opposite, healthy breast.”
Overall survival was not significantly different in MA.17R between the two groups but Dr. Goss notes that because of the slow chronic relapsing nature of hormone-receptor positive breast cancer, overall survival has proved difficult to demonstrate in clinical trials.
Because of this, most endocrine therapies for breast cancer have gained regulatory approval based solely on improvement of disease-free survival.
Patient overall quality of life was comparable between the two groups.
Small differences in physical role functioning in favour of placebo was observed but these were not considered clinically significant.
“A large proportion of women with early breast cancer are long-term survivors. As hormone therapy is given over a long period of time, measuring how women feel is very important,” said Julie Lemieux, MD, lead author of the analysis of patient-reported outcomes from MA.17R, and a researcher at the Centre hospitalier universitaire de Québec in Canada.
About the Study
Data from two related abstracts from the MA.17R clinical trial were be presented at the Annual Meeting, with the first reporting on safety and efficacy outcomes (LBA1 - Plenary) and the second reporting patient quality of life outcomes (LBA506).
The trial enrolled 1,918 postmenopausal women who had received five years of any one of three AI therapies either as initial treatment or after any duration of prior tamoxifen.
Although patients were allowed to enroll up to two years after completing previous AI therapy, about 90% began receiving letrozole or placebo within six months of completing prior therapy.
Patient-reported quality of life was measured using the standard SF-36 questionnaire, which covers various areas of physical health and mental health, and a menopause-specific questionnaire, MENQOL.
Of the 1,918 study participants, 1,428 were eligible to complete initial quality of life assessments.
These were repeated at 12, 24, 36, 48 and 60 months, with more than 85% of women completing the questionnaires at follow-up.
Impact on Risk of Recurrence and New Breast Cancer (LBA1 - Plenary): Women in the extended letrozole group had a 34% lower risk of breast cancer recurrence.
The annual incidence of contralateral breast cancer, was lower in the letrozole group than in the placebo group (0.21% vs. 0.49%), indicating a breast cancer prevention effect.
At five years of follow-up, 95% of women receiving letrozole and 91% of those receiving placebo were breast cancer free.
The five-year overall survival was 93% for women receiving placebo and 94% for those receiving letrozole (not statistically significant).
Quality of Life Findings (LBA506): Overall, there were no significant differences in either overall quality of life or menopause-specific quality of life between women who took letrozole for five years and those who received placebo.
Small differences in physical role functioning were detected in favour of placebo but these were less than that considered clinically meaningful.
In 2012, there were more than six million women around the world who survived at least five years after breast cancer diagnosis; the vast majority of these women have oestrogen receptor-positive breast cancer, and may wish to consider these findings.